# Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin

> **NCT06677190** · PHASE2 · RECRUITING · sponsor: **Dana-Farber Cancer Institute** · enrollment: 32 (estimated)

## Conditions studied

- Ovarian Cancer
- Ovarian Carcinoma
- Endometrial Cancer
- Uterine Cancer
- Cervical Cancer
- Vulvar Cancer
- Gynecologic Cancer
- Vaginal Cancer

## Interventions

- **DRUG:** Belzutifan

## Key facts

- **NCT ID:** NCT06677190
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-20
- **Primary completion:** 2026-12-30
- **Final completion:** 2029-06-30
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2025-11-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06677190

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06677190, "Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT06677190. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*